首页> 外文OA文献 >Synthesis, characterization and biological evaluation of N-ferrocenylmethyl amino acid benzene carboxamide derivatives and N-ferrocenyl benzoyl amino alkane derivatives as anti-cancer agents.
【2h】

Synthesis, characterization and biological evaluation of N-ferrocenylmethyl amino acid benzene carboxamide derivatives and N-ferrocenyl benzoyl amino alkane derivatives as anti-cancer agents.

机译:N-二茂铁甲基氨基酸苯甲酰胺衍生物和N-二茂铁基苯甲酰氨基链烷衍生物作为抗癌剂的合成,表征和生物学评价。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of this research was to explore the structure-activity relationship (SAR) of ferrocenyl-bioconjugates. A series of N-(ferrocenylmethylamino acid)-fluorinated-benzene carboxamide derivatives and a series of N-(ferrocenyl)-benzoyl-aminoalkane derivatives have been synthesised, structurally characterised and biologically evaluated for their anti-proliferative activity on various cancer cell lines, principally, the (estrogen receptor positive) MCF-7 breast cancer cell line. udThe anti-cancer effect of ferrocene is due to the generation of a reactive oxygenated species. As part of the primary SAR study, a series of N-(ferrocenylmethylamino acid)-fluorinated-benzene carboxamide derivatives have been synthesised, structurally characterised and biologically evaluated. This series involved the attachment of amino acids, such as glycine, L-alanine and β-alanine and also a fluorobenzoyl unit to a ferrocenylmethylamine moiety in order to enhance the bioavailability of the compounds thus increasing their anti-cancer effect. The synthesis of N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide derivatives was achieved by coupling the free N-terminus of the ferrocenylmethylamine with the carboxylic acid group of the N-(fluorobenzoyl)-amino acid using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and 1-hydroxybenzotriazole (HOBt) coupling protocol. All compounds were characterised by a range of spectroscopic techniques including: 1H, 13C, 19F, DEPT-135, and HMQC NMR in addition to IR, UV, and MSudThe attachment of a benzoyl spacer lowers the redox potential of the ferrocene moiety thus making the iron atom between the cyclopentadienyl rings, easier and more accessible to oxidation. A series of N-{(ferrocenyl)-benzoyl}-aminoalkanes have also been synthesised and characterised and biologically evaluated on the MCF-7 breast cancer cell line. The main aim was to conduct a structure activity relationship on two key moieties of the molecules, the difference of the substitution pattern around the aromatic benzoyl moiety and also the attachment of the various aminoalkanes, in hope that the biological activity will show a greater anti-proliferative effect against cancer cell lines. The synthesis of the N-{(ferrocenyl)-benzoyl}-aminoalkanes derivatives involved the coupling of the free N-terminus of the amine group of the aminoalkanes to the carboxylic acid group of the ferrocenyl-benzoic acid (ortho-, meta- and para-) using N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (NHS) coupling protocol. All compounds were also characterised by the spectroscopic methods as mentioned above.udFor the biological evaluation of the N-(ferrocenylmethylamino acid) fluorinated benzene carboxamide series of compounds, were tested on the estrogen positive (ER+) breast cancer cell line, MCF-7. Three libraries of novel ferrocene compounds were prepared by incorporating the glycine, L-alanine and β-alanine amino acids and the fluorobenzoyl moiety with the fluorine at the positions 2, 3, 4, (2,6), (2,4), (3,5), (3,4,5) and (2,3,4,5,6). All three libraries were tested in vitro. For comparative reasons, N-(ferrocenylmethyl)-4-fluorobenzene carboxamide, the most active compound from a previous SAR study on the MBA-MD-435-SF, ER(+) breast cancer cell line was also tested to observe the effect from the addition of the amino acid into the model structure. In total of the three libraries tested, there were four active compounds, with N-(ferrocenylmethylalanine)-3,4,5-trifluorobenzene carboxamide being the most active giving an IC50 value of 2.4 µM. This derivative also induced a block in the G2/M phase of the cell cycle. This series of compounds were also screened in vitro for their anti-proliferative effect against the non-small cell lung cancer cell line, H1299 at two concentrations, 10 µM and 1 µM. There was no activity below either of the concentrations and the study was stopped. The biological evaluation of N-{(ferrocenyl)-benzoyl}-aminoalkanes were screened in vitro on the MCF-7 breast cancer cell line. Preliminary screens showed that this type of compound had an anti-proliferative effect on MCF-7 breast cancer cell line. From 27 derivatives synthesised, IC50 data values were achieved. The ortho- series produced eight derivatives having an anti-proliferative effect, six of which were in the range of 2 µM to 6 µM. The meta- series produced two derivatives, with IC50 values of 51.5 µM and 51.2 µM. The para- derivatives also produced eight derivatives having an anti-proliferative effect, three of which were in the range of 2 µM to 6 µM. The most active derivative synthesised was N-{para-(ferrocenyl)-benzoyl}-aminooctane, with an IC50 of 1.10 µM.ududududud
机译:这项研究的目的是探索二茂铁基-生物共轭物的结构-活性关系(SAR)。已合成了一系列N-(二茂铁基甲基氨基酸)-氟化苯甲酰胺衍生物和一系列N-(二茂铁基)-苯甲酰基-氨基烷烃衍生物,对其结构进行了表征,并对其生物学活性进行了评估,从而可用于各种癌细胞系,主要是(雌激素受体阳性)MCF-7乳腺癌细胞系。 ud二茂铁的抗癌作用归因于反应性氧化物质的产生。作为主要SAR研究的一部分,已经合成了一系列N-(二茂铁基甲基氨基酸)-氟化苯甲酰胺衍生物,对其结构进行了表征并对其进行了生物学评估。该系列涉及将氨基酸如甘氨酸,L-丙氨酸和β-丙氨酸以及氟苯甲酰基单元连接至二茂铁基甲胺部分,以增强化合物的生物利用度,从而提高其抗癌作用。 N-(二茂铁基甲基氨基酸)氟化苯甲酰胺衍生物的合成是通过使用N-(3-二甲基氨基丙基)-N将二茂铁基甲胺的游离N-末端与N-(氟苯甲酰基)-氨基酸的羧酸基偶联而实现的'-乙基碳二亚胺盐酸盐(EDC)和1-羟基苯并三唑(HOBt)偶联方案。所有化合物均通过一系列光谱技术进行了表征,这些技术包括:IR,UV和MS ud之外的1H,13C,19F,DEPT-135和HMQC NMR。苯甲酰基间隔基的附着降低了二茂铁部分的氧化还原电势,因此使环戊二烯基环之间的铁原子更容易被氧化。一系列的N-{(二茂铁基)-苯甲酰基}-氨基烷烃也已被合成,表征并在MCF-7乳腺癌细胞系上进行了生物学评估。主要目的是在分子的两个关键部分上建立结构活性关系,即芳族苯甲酰基部分周围取代模式的差异以及各种氨基烷烃的附着,以期生物学活性将显示出更大的抗-对癌细胞系的增殖作用。 N-{(二茂铁基)-苯甲酰基}-氨基链烷烃衍生物的合成涉及氨基烷烃的胺基的游离N-末端与二茂铁基苯甲酸的羧酸基团(邻,间和间)的偶联。对-),使用N-(3-二甲基氨基丙基)-N'-乙基碳二亚胺盐酸盐(EDC)和N-羟基琥珀酰亚胺(NHS)偶联方案。所有化合物还通过上述光谱学方法进行表征。 ud对于N-(二茂铁基甲基氨基酸)氟化苯甲酰胺系列化合物的生物学评估,在雌激素阳性(ER +)乳腺癌细胞MCF-7上进行了测试。通过将甘氨酸,L-丙氨酸和β-丙氨酸氨基酸以及氟苯甲酰基部分与氟在2、3、4,(2,6),(2,4), (3,5),(3,4,5)和(2,3,4,5,6)。所有三个库均在体外测试。出于比较原因,还对N-(二茂铁基甲基)-4-氟苯甲酰胺(一种先前对MBA-MD-435-SF,ER(+)乳腺癌细胞进行SAR研究的活性最强的化合物)进行了测试,以观察将氨基酸添加到模型结构中。在测试的三个文库中,总共有四种活性化合物,其中N-(二茂铁基甲基丙氨酸)-3,4,5-三氟苯甲酰胺活性最高,IC50值为2.4 µM。该衍生物还诱导了细胞周期的G2 / M期的阻断。还对该化合物系列进行了体外筛选,以检测其对非小细胞肺癌细胞系H1299的抗增殖作用,两种浓度分别为10 µM和1 µM。低于任何一个浓度都没有活性,并且停止研究。在MCF-7乳腺癌细胞系上体外筛选了N-{(二茂铁基)-苯甲酰基}-氨基链烷烃的生物学评估。初步筛选显示,这类化合物对MCF-7乳腺癌细胞系具有抗增殖作用。从合成的27种衍生物中,获得了IC50数据值。邻系列产生了八种具有抗增殖作用的衍生物,其中六种在2 µM至6 µM的范围内。 meta系列产生了两种衍生物,IC50值为51.5 µM和51.2 µM。对衍生物还产生了具有抗增殖作用的八种衍生物,其中三种在2 µM至6 µM的范围内。合成的活性最高的衍生物是N- {对-(二茂铁基)-苯甲酰基}-氨基辛烷,IC50为1.10 µM。 ud ud ud ud ud

著录项

  • 作者

    Butler William E.;

  • 作者单位
  • 年度 2012
  • 总页数
  • 原文格式 PDF
  • 正文语种 en
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号